Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.6.2161

Sequence to Structure Approach of Estrogen Receptor Alpha and Ligand Interactions  

Chamkasem, Aekkapot (Faculty of Veterinary Science, Mahidol University)
Toniti, Waraphan (Department of Pre-clinic and Applied Animal Sciences, Faculty of Veterinary Science, Mahidol University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.6, 2015 , pp. 2161-2166 More about this Journal
Abstract
Estrogen receptors (ERs) are steroid receptors located in the cytoplasm and on the nuclear membrane. The sequence similarities of human $ER{\alpha}$, mouse $ER{\alpha}$, rat $ER{\alpha}$, dog $ER{\alpha}$, and cat $ER{\alpha}$ are above 90%, but structures of $ER{\alpha}$ may different among species. Estrogen can be agonist and antagonist depending on its target organs. This hormone play roles in several diseases including breast cancer. There are variety of the relative binding affinity (RBA) of ER and estrogen species in comparison to $17{\beta}-estradiol$ (E2), which is a natural ligand of both $ER{\alpha}$ and $ER{\beta}$. The RBA of the estrogen species are as following: diethyl stilbestrol (DES) > hexestrol > dienestrol > $17{\beta}-estradiol$ (E2) > 17- estradiol > moxestrol > estriol (E3) >4-OH estradiol > estrone-3-sulfate. Estrogen mimetic drugs, selective estrogen receptor modulators (SERMs), have been used as hormonal therapy for ER positive breast cancer and postmenopausal osteoporosis. In the postgenomic era, in silico models have become effective tools for modern drug discovery. These provide three dimensional structures of many transmembrane receptors and enzymes, which are important targets of de novo drug development. The estimated inhibition constants (Ki) from computational model have been used as a screening procedure before in vitro and in vivo studies.
Keywords
$ER{\alpha}$; in silico model; SERMs; binding affinity;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Anstead GM, Carlson KE, Katzenellenbogen JA (1997). The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids, 62, 268-303.   DOI
2 Arnal JF, Valera MC, Payrastre B, et al (2012). Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models. Thromb Res, 130, 7-11.   DOI
3 Ascenzi P, Bocedi A, Marino M (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med, 27, 299-402.   DOI
4 LaFrate AL, Carlson KE, Katzenellenbogen JA (2009). Steroidal bivalent ligands for the estrogen receptor: design, synthesis, characterization and binding affinities. Bioorg Med Chem, 17, 3528-35.   DOI
5 Leinonen R, Nardone F, Zhu W, et al (2006). UniSave: the UniProtKB sequence/annotation version database. Bioinformatics, 22, 1284-5.   DOI
6 Lewis DF, Ogg MS, Goldfarb PS, et al (2002). Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement. J Steroid Biochem Mol Biol, 82, 195-9.   DOI
7 Li X, Huang J, Yi P, et al (2004). Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol, 24, 7681-94.   DOI
8 Madeira KP, Daltoe RD, Sirtoli GM, et al (2012). Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer. Pathol Res Pract, 208, 657-61.   DOI
9 Maggiolini M, Bonofiglio D, Marsico S, et al (2001). Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol, 60, 595-602.
10 Meshram RJ, Bhiogade NH, Gacche RN, et al (2012). Virtual screening and docking exploration on estrogen receptor: An in silico approach to decipher novel anticancer agents. Indian J Biotechnol, 11, 389-95.
11 Millanta F, Calandrella M, Bari G, et al (2005). Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci, 79, 225-32.   DOI
12 Zhang X, Spiegelman D, Baglietto L, et al (2012). Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr, 95, 713-25.   DOI
13 Tremollieres F, Lopes P (2002). [Specific estrogen receptor modulators (SERMs)]. Presse Med, 31, 1323-8.
14 UniProt C (2014). Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res, 42, 191-8.   DOI
15 Xu CY, Jiang ZN, Zhou Y, et al (2013). Estrogen receptor alpha roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52.   DOI   ScienceOn
16 Brzozowski AM, Pike AC, Dauter Z, et al (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-8.   DOI
17 Barkhem T, Carlsson B, Nilsson Y, et al (1998). Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol, 54, 105-12.
18 Berman HM, Westbrook J, Feng Z, et al (2000). The Protein Data Bank. Nucleic Acids Res, 28, 235-42.   DOI
19 Bollig-Fischer A, Thakur A, Sun Y, et al (2012). The Predominant Proteins that React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight between the Mammary Gland and Uterus in the Mouse and Rat. Int J Biomed Sci, 8, 51-63.
20 Cao X, Jiang J, Zhang S, et al (2013). Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett, 23, 3329-33.   DOI
21 Chakraborty S, Cole S, Rader N, et al (2012). In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface. Mol Divers, 16, 441-51.   DOI
22 Chitrala KN, Yeguvapalli S (2013). Prediction and analysis of ligands against estrogen related receptor alpha. Asian Pac J Cancer Prev, 14, 2371-5.   DOI
23 Czeczuga-Semeniuk E, Jarzabek K, Lemancewicz D, et al (2009). The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. Gynecol Endocrinol, 25, 287-93.   DOI
24 D'Amelio P, Isaia GC (2013). The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother, 14, 949-56.   DOI
25 Osborne CK, Zhao H, Fuqua SA (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 18, 3172-86.
26 Nam K, Marshall P, Wolf RM, et al (2003). Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma. Biopolymers, 68, 130-8.   DOI
27 Nam KH, Huang Q, Ke A (2012). Nucleic acid binding surface and dimer interface revealed by CRISPR-associated CasB protein structures. FEBS Lett, 586, 3956-61.   DOI
28 Nose T, Tokunaga T, Shimohigashi Y (2009). Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate. Toxicol Lett, 191, 33-9.   DOI
29 Pieper U, Eswar N, Braberg H, et al (2004). MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res, 32, 217-22.
30 Pike AC, Brzozowski AM, Hubbard RE, et al (1999). Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J, 18, 4608-18.   DOI
31 Rehm S, Solleveld HA, Portelli ST, et al (2007). Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene. Birth Defects Res B Dev Reprod Toxicol, 80, 225-32.   DOI
32 Rustici G, Kolesnikov N, Brandizi M, et al (2013). ArrayExpress update--trends in database growth and links to data analysis tools. Nucleic Acids Res, 41, 987-90.   DOI
33 Gangloff M, Ruff M, Eiler S, et al (2001). Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem, 276, 15059-65.   DOI
34 de Villiers TJ, Gass ML, Haines CJ, et al (2013). Global Consensus Statement on menopausal hormone therapy. Maturitas, 74, 391-2.   DOI
35 Eliassen AH, Hendrickson SJ, Brinton LA, et al (2012). Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst, 104, 1905-16.   DOI
36 Frasor J, Barnett DH, Danes JM, et al (2003). Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinol, 144, 3159-66.   DOI
37 Gaudet P, Lane L, Fey P, et al (2009). Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford), 2009, 16.
38 Hendrickson SJ, Hazra A, Chen C, et al (2012). beta-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 96, 1379-89.   DOI
39 Illera JC, Perez-Alenza MD, Nieto A, et al (2006). Steroids and receptors in canine mammary cancer. Steroids, 71, 541-8.   DOI
40 Kuiper G, Carlsson B, Grandien K, et al (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol, 138, 863-70.
41 Kumar R, Thompson EB (1999). The structure of the nuclear hormone receptors. Steroids, 64, 310-9.   DOI
42 Kumar R, Zakharov MN, Khan SH, et al (2011). The dynamic structure of the estrogen receptor. J Amino Acids, 2011, 812540.
43 Sievers F, Wilm A, Dineen D, et al (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol, 7, 539.
44 Rybalchenko V, Grillo MA, Gastinger MJ, et al (2009). The unliganded long isoform of estrogen receptor beta stimulates brain ryanodine receptor single channel activity alongside with cytosolic Ca2+. J Recept Signal Transduct Res, 29, 326-41.   DOI
45 Schnell S, Mendoza C (2001). A fast method to estimate kinetic constants for enzyme inhibitors. Acta Biotheor, 49, 109-13.   DOI
46 Shiau AK, Barstad D, Loria PM, et al (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-37.   DOI
47 Stump AL, Kelley KW, Wensel TM (2007). Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother, 41, 833-9.   DOI
48 Suganya J, Radha M, Naorem DL, et al (2014). In Silico docking studies of selected flavonoids-- natural healing agents against breast cancer. Asian Pac J Cancer Prev, 15, 8155-9.   DOI
49 Thompson JD, Higgins DG, Gibson TJ (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res, 22, 4673-80.   DOI
50 Toniti W, Suthiyotha N, Puchadapirom P, et al (2011). Binding capacity of ER-alpha ligands and SERMs: comparison of the human, dog and cat. Asian Pac J Cancer Prev, 12, 2875-9.
51 Touraine P (2003). [SERMs and uterus]. Ann Med Interne (Paris), 154, 103-8.